Servier, a French pharmaceutical company, and National Company KAZAKH INVEST JSC have signed an agreement on cooperation in the area of pharmaceutical manufacturing.
The parties discussed potential transfer of innovative pharmaceutical manufacturing technologies of Servier to the Republic of Kazakhstan and agreed on the investment strategy for localization of medicinal products.
“The development and strengthening of cooperation with the Republic of Kazakhstan, where we have been operating for more than 20 years, is one of the main priorities for Servier. Currently, we are discussing potential investments with the Government of Kazakhstan, and we already held a series of fruitful negotiations and signed an Agreement on Cooperation with Kazakh INVEST JSC. We are ready to offer not only the transfer of innovative technologies for manufacturing original medicines, but also modern solutions to improve treatment effectiveness for the chronic non-infectious diseases, such as cardiovascular diseases, diabetes mellitus, etc. I am sure that the Agreement on Cooperation is an important step towards improving the availability of high quality innovative solutions for the people of the Republic of Kazakhstan,” said Jérôme Gavet, Managing Director of Servier in EAEU.
The next step in the bilateral relations will be the development of a roadmap that will define the stages and period for implementation of investment project to launch the local manufacturing of innovative medicines of Servier in Kazakhstan.